BACKGROUND: Intratumoral hemorrhage, as one of the cerebrovascular complications in various tumor-related conditions, occurs mainly in malignant brain tumors. Recent studies have shown that the overexpression of vascular endothelial growth factor (VEGF) and metalloproteinase (MMP) may play a role for the loss of vascular integrity and the subsequent hemorrhage in several instances, in addition to their well-known properties in tumor development and metastasis. METHODS: To investigate the potential role of VEGF and MMP in hemorrhagic complication of metastatic brain tumor, we estimated the expression of VEGF, MMP-2 & -9 by immunohistochemical studies in pathological specimens of metastatic brain tumors obtained from 16 patients, 7 in hemorrhagic and 9 in non-hemorrhagic group. We also examined the expression of collagen type IV, CD34, Factor VIII in order to evaluate the status of tumor vasculature. RESULTS: Patients in hemorrhagic group showed a higher VEGF expression with neovascularization than those in non-hemorrhagic group. The basement membranes of newly formed vessels were disrupted in cases with high expression in both MMP-2 and -9. These results indicate that rapid growing nascent blood vessels, responding vigorously to VEGF, are concentrated around the hemorrhagic tumors. Besides, these results suggest a possibility that the basement membranes of these nascent vessels could be disrupted proteolytically by MMP. CONCLUSION: We conclude that overexpression of VEGF and MMP may play a role in metastatic brain tumor-associated hemorrhage. Presumably, the underlying pathophysiological mechanisms are through rapid growth and breakdown of vessels around the tumors caused by overexpression of VEGF and MMP of tumor cells.
BACKGROUND: Intratumoral hemorrhage, as one of the cerebrovascular complications in various tumor-related conditions, occurs mainly in malignant brain tumors. Recent studies have shown that the overexpression of vascular endothelial growth factor (VEGF) and metalloproteinase (MMP) may play a role for the loss of vascular integrity and the subsequent hemorrhage in several instances, in addition to their well-known properties in tumor development and metastasis. METHODS: To investigate the potential role of VEGF and MMP in hemorrhagic complication of metastatic brain tumor, we estimated the expression of VEGF, MMP-2 & -9 by immunohistochemical studies in pathological specimens of metastatic brain tumors obtained from 16 patients, 7 in hemorrhagic and 9 in non-hemorrhagic group. We also examined the expression of collagen type IV, CD34, Factor VIII in order to evaluate the status of tumor vasculature. RESULTS:Patients in hemorrhagic group showed a higher VEGF expression with neovascularization than those in non-hemorrhagic group. The basement membranes of newly formed vessels were disrupted in cases with high expression in both MMP-2 and -9. These results indicate that rapid growing nascent blood vessels, responding vigorously to VEGF, are concentrated around the hemorrhagic tumors. Besides, these results suggest a possibility that the basement membranes of these nascent vessels could be disrupted proteolytically by MMP. CONCLUSION: We conclude that overexpression of VEGF and MMP may play a role in metastatic brain tumor-associated hemorrhage. Presumably, the underlying pathophysiological mechanisms are through rapid growth and breakdown of vessels around the tumors caused by overexpression of VEGF and MMP of tumor cells.
Authors: Tomoki Hashimoto; Gen Wen; Michael T Lawton; Nancy J Boudreau; Andrew W Bollen; Guo-Yuan Yang; Nicholas M Barbaro; Randall T Higashida; Christopher F Dowd; Van V Halbach; William L Young Journal: Stroke Date: 2003-03-20 Impact factor: 7.914
Authors: D Kondziolka; M Bernstein; L Resch; C H Tator; J F Fleming; R G Vanderlinden; H Schutz Journal: J Neurosurg Date: 1987-12 Impact factor: 5.115
Authors: J A Curci; D Mao; D G Bohner; B T Allen; B G Rubin; J M Reilly; G A Sicard; R W Thompson Journal: J Vasc Surg Date: 2000-02 Impact factor: 4.268
Authors: Klaus Mayerhofer; Plamen Lozanov; Klaus Bodner; Barbara Bodner-Adler; Nika Mayerhofer-Gallenbacher; Gernot Hudelist; Klaus Czerwenka Journal: Anticancer Res Date: 2003 Jul-Aug Impact factor: 2.480
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245
Authors: Aaron M Gusdon; Paul A Nyquist; Victor M Torres-Lopez; Audrey C Leasure; Guido J Falcone; Kevin N Sheth; Lauren H Sansing; Daniel F Hanley; Rachna Malani Journal: Stroke Date: 2019-11-20 Impact factor: 7.914
Authors: Ben G McGahan; Beth K Neilsen; David L Kelly; Rodney D McComb; S A Jaffar Kazmi; Matt L White; Yan Zhang; Michele R Aizenberg Journal: J Neurooncol Date: 2017-01-19 Impact factor: 4.130
Authors: Masato Sasaki; Christiane B Knobbe; Momoe Itsumi; Andrew J Elia; Isaac S Harris; Iok In Christine Chio; Rob A Cairns; Susan McCracken; Andrew Wakeham; Jillian Haight; Annick You Ten; Bryan Snow; Takeshi Ueda; Satoshi Inoue; Kazuo Yamamoto; Myunggon Ko; Anjana Rao; Katharine E Yen; Shinsan M Su; Tak Wah Mak Journal: Genes Dev Date: 2012-08-27 Impact factor: 11.361